Key Facts Surrounding This News Item
- CKPT had returned +44.33% year-to-date leading up to today’s news, versus a +2.26% return from the benchmark S&P 500 during the same period.
More Info About Checkpoint Therapeutics, Inc. (CKPT)
Checkpoint Therapeutics, Inc., an immuno-oncology biopharmaceutical company, focuses on the acquisition, development, and commercialization of non-chemotherapy and immune-enhanced combination treatments for patients with solid tumor cancers. The company was founded in 2014 and is based in New York, New York. Checkpoint Therapeutics, Inc. is a subsidiary of Fortress Biotech, Inc. View our full CKPT ticker page with ratings, news, and more.